Guruprasad P Aithal

List of Publications by Citations

205 papers	11,812 citations	50 h-index	107 g-index
232 ext. papers	14,815 ext. citations	6.6 avg, IF	6.36 L-index

#	Paper	IF	Citations
205	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet, The*, **1999**, 353, 717-9	40	1066
204	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet, The*, **2016**, 387, 679-690	40	935
203	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nature Genetics*, **2009**, 41, 816-9	36.3	818
202	Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology*, **2008**, 135, 1176-84	13.3	516
201	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology*, **2008**, 47, 455-60	11.2	494
200	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology*, **2018**, 67, 1754-1767	11.2	376
199	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nature Communications*, **2014**, 5, 4309	17.4	362
198	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, **2011**, 141, 338-47	13.3	359
197	EASL Clinical Practice Guidelines: Drug-induced liver injury. *Journal of Hepatology*, **2019**, 70, 1222-1261	13.4	327
196	Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. *Gastroenterology*, **2007**, 132, 272-81	13.3	277
195	Drug-induced liver injury: recent advances in diagnosis and risk assessment. *Gut*, **2017**, 66, 1154-1164	19.2	250
194	Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *Journal of Clinical and Experimental Hepatology*, **2013**, 3, 37-49	4.1	225
193	Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. *Hepatology*, **2004**, 39, 1430-40	11.2	188
192	Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. *Gastroenterology*, **2019**, 156, 2230-2241.e11	13.4	184
191	Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017. *Endoscopy*, **2017**, 49, 989-1006	3.4	182
190	Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. *Endoscopy*, **2017**, 49, 695-714	3.4	166
189	Drug-induced liver injury. *Nature Reviews Disease Primers*, **2019**, 5, 58	51.1	148

188	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, **2017**, 152, 1078-1089	13.3	137
187	No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. *Gastroenterology*, **2013**, 145, 1016-1025.e2	13.3	131
186	Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. *Journal of Hepatology*, **2008**, 49, 732-8	13.4	128
185	Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. *Clinics in Liver Disease*, **2007**, 11, 563-75, vi-vii	4.6	117
184	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. *Hepatology*, **2020**, 72, 892-905	11.2	116
183	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. *Journal of Hepatology*, **2010**, 53, 1049-53	13.4	114
182	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *Journal of Hepatology*, **2020**, 73, 505-515	13.4	113
181	Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated August 2018. *Endoscopy*, **2019**, 51, 179-193	3.4	109
180	Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. *Journal of Hepatology*, **2000**, 33, 949-52	13.4	108
179	Hepatotoxicity related to antirheumatic drugs. *Nature Reviews Rheumatology*, **2011**, 7, 139-50	8.1	106
178	Accuracy of hepatic adverse drug reaction reporting in one English health region. *BMJ: British Medical Journal*, **1999**, 319, 1541		102
177	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. *Hepatology*, **2019**, 69, 1075-1086	11.2	100
176	Efficacy, safety, and predictive factors for a positive yield of EUS-guided Trucut biopsy: a large tertiary referral center experience. *American Journal of Gastroenterology*, **2009**, 104, 584-91	0.7	100
175	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. *Pharmacogenetics and Genomics*, **2012**, 22, 784-95	1.9	96
174	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics and Genomics*, **2000**, 10, 511-8		96
173	Genetic basis of drug-induced liver injury: present and future. *Seminars in Liver Disease*, **2014**, 34, 123-33	7.3	95
172	Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. *Gastrointestinal Endoscopy*, **2002**, 55, 648-54	5.2	94
171	All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. *Liver International*, **2012**, 32, 79-84	7.9	89

170	1 and 5 year survival estimates for people with cirrhosis of the liver in England, 1998-2009: a large population study. *Journal of Hepatology*, **2014**, 60, 282-9	13.4	82
169	Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. *Pharmacogenetics and Genomics*, **2004**, 14, 813-22		82
168	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. *Hepatology*, **2013**, 57, 103-11	11.2	81
167	Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. *Journal of Hepatology*, **2004**, 41, 685-6	13.4	81
166	Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 288-297	18.8	80
165	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. *Journal of Hepatology*, **2017**, 67, 137-144	13.4	78
164	Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. *Gastroenterology*, **2006**, 131, 1752-7	13.3	71
163	A study of T□relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. *NMR in Biomedicine*, **2015**, 28, 706-14	4.4	69
162	Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. *BMJ Open*, **2015**, 5, e007516	3	66
161	Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. *Hepatology*, **2007**, 46, 1131-7	11.2	63
160	Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. *Journal of Hepatology*, **2016**, 65, 1131-1139	13.4	61
159	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. *Gastroenterology*, **2019**, 156, 1707-1716.e2	13.3	59
158	Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. *Liver International*, **2015**, 35, 1801-8	7.9	53
157	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. *Journal of Hepatology*, **2019**, 71, 1141-1151	13.4	51
156	A role for the pregnane X receptor in flucloxacillin-induced liver injury. *Hepatology*, **2010**, 51, 1656-64	11.2	50
155	HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. *Pharmacogenetics and Genomics*, **2016**, 26, 218-24	1.9	50
154	Lower gut microbiome diversity and higher abundance of proinflammatory genus are associated with biopsy-proven nonalcoholic steatohepatitis. *Gut Microbes*, **2020**, 11, 569-580	8.8	49
153	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. *European Journal of Clinical Pharmacology*, **2014**, 70, 1079-86	2.8	48

152	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. *Hepatology*, **2020**, 72, 88-102	11.2	46
151	Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. *Journal of Hepatology*, **2018**, 69, 948-957	13.4	45
150	Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. *American Journal of Gastroenterology*, **2008**, 103, 2784-8	0.7	44
149	Guidelines on the management of ascites in cirrhosis. *Gut*, **2021**, 70, 9-29	19.2	43
148	The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2007**, 451, 943-8	5.1	41
147	Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. *Gastrointestinal Endoscopy*, **2002**, 56, 701-7	5.2	41
146	Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 395-409	5.5	40
145	Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 350, 387-402	4.7	39
144	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. *Digestive Diseases and Sciences*, **2001**, 46, 1520-5	4	39
143	Role of Drugs Used for Chronic Disease Management on Susceptibility and Severity of COVID-19: A Large Case-Control Study. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 1185-1194	6.1	39
142	Natural history of histologically proven alcohol-related liver disease: A systematic review. *Journal of Hepatology*, **2019**, 71, 586-593	13.4	38
141	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 245-253	6.1	35
140	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1028-1036	6.1	34
139	Causality assessment for suspected DILI during clinical phases of drug development. *Drug Safety*, **2014**, 37 Suppl 1, S47-56	5.1	34
138	Polygenic architecture informs potential vulnerability to drug-induced liver injury. *Nature Medicine*, **2020**, 26, 1541-1548	50.5	34
137	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. *BMJ Open*, **2017**, 7, e015659	3	33
136	Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?. *American Journal of Clinical Dermatology*, **2005**, 6, 357-63	7.1	33
135	Increased liver fat and glycogen stores after consumption of high versus low glycaemic index food: A randomized crossover study. *Diabetes, Obesity and Metabolism*, **2017**, 19, 70-77	6.7	31

134	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*, **2021**,	19.2	31
133	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. *Lancet, The*, **2020**, 395, 226-239	40	28
132	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemporary Clinical Trials*, **2020**, 98, 106175	2.3	28
131	Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. *Hepatology*, **2014**, 60, 158-68	11.2	27
130	Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 504-515	6.1	27
129	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. *Journal of Hepatology*, **2020**, 73, 231-240	13.4	26
128	The influence of adiposity and acute exercise on circulating hepatokines in normal-weight and overweight/obese men. *Applied Physiology, Nutrition and Metabolism*, **2018**, 43, 482-490	3	25
127	Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. *Journal of Hepatology*, **2018**, 69, 1015-1024	13.4	24
126	Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. *Pancreas*, **2009**, 38, 267-74	2.6	24
125	Multicenter experience from the UK and Ireland of use of lumen-apposing metal stent for transluminal drainage of pancreatic fluid collections. *Endoscopy International Open*, **2018**, 6, E259-E265	3	23
124	Effect of exercise intensity on circulating hepatokine concentrations in healthy men. *Applied Physiology, Nutrition and Metabolism*, **2019**, 44, 1065-1072	3	19
123	CYP2C9 polymorphism and warfarin dose requirements. *British Journal of Clinical Pharmacology*, **2002**, 53, 408-9	3.8	19
122	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. *American Journal of Gastroenterology*, **2019**, 114, 1744-1752	0.7	19
121	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. *Hepatology*, **2021**, 73, 268-281	11.2	19
120	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2021**, 75, 770-785	13.4	19
119	Dynamics of 5-carboxylcytosine during hepatic differentiation: Potential general role for active demethylation by DNA repair in lineage specification. *Epigenetics*, **2017**, 12, 277-286	5.7	18
118	The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway?. *International Journal of Hepatology*, **2012**, 2012, 624675	2.7	18
117	Dangerous liaisons: drug, host and the environment. *Journal of Hepatology*, **2007**, 46, 995-8	13.4	18

116	EUS-guided Trucut mural biopsies in the investigation of unexplained thickening of the esophagogastric wall. *Gastrointestinal Endoscopy*, **2005**, 62, 624-9	5.2	18
115	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. *Hepatology*, **2021**, 73, 1920-1931	11.2	18
114	Safety and long term efficacy of porfimer sodium photodynamic therapy in locally advanced biliary tract carcinoma. *Photodiagnosis and Photodynamic Therapy*, **2012**, 9, 287-92	3.5	17
113	Genetic regulation of warfarin metabolism and response. *Seminars in Vascular Medicine*, **2003**, 3, 231-8		17
112	Warfarin dose requirement and CYP2C9 polymorphisms. *Lancet, The*, **1999**, 353, 1972-1973	40	17
111	Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis. *Seminars in Liver Disease*, **2015**, 35, 421-31	7.3	16
110	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. *Science Translational Medicine*, **2021**, 13, eabj0847	17.5	16
109	Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1179-1183	6.7	15
108	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. *Frontline Gastroenterology*, **2017**, 8, 252-259	2.6	15
107	Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. *Journal of Clinical and Experimental Hepatology*, **2019**, 9, 515-521	4.1	15
106	Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. *Hepatology International*, **2021**, 15, 258-282	8.8	15
105	Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage. *European Journal of Gastroenterology and Hepatology*, **2013**, 25, 201-7	2.2	14
104	Efficacy, Safety, and Predictive Factors for a Positive Yield of EUS-Guided Trucut Biopsy. *American Journal of Gastroenterology*, **2009**, 104, 584-591	0.7	14
103	Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2330-2338.e1	6.9	13
102	Acute Hyperenergetic, High-Fat Feeding Increases Circulating FGF21, LECT2, and Fetuin-A in Healthy Men. *Journal of Nutrition*, **2020**, 150, 1076-1085	4.1	12
101	Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK. *Liver International*, **2018**, 38, 1686-1695	7.9	12
100	Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease. *European Journal of Applied Physiology*, **2018**, 118, 817-828	3.4	12
99	Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 107-115	2.4	12

98	Glycaemic, gastrointestinal and appetite responses to breakfast porridges from ancient cereal grains: A MRI pilot study in healthy humans. *Food Research International*, **2019**, 118, 49-57	7	12
97	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1125-1135	6.1	12
96	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. *Journal of Hepatology*, **2021**, 74, 972-974	13.4	12
95	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. *Gut*, **2021**,	19.2	11
94	Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study. *Journal of Gastroenterology*, **2017**, 52, 1192-1200	6.9	10
93	When is a herb a drug?. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 391-3	2.2	10
92	Immune dysfunction in patients with obstructive jaundice before and after endoscopic retrograde cholangiopancreatography. *Clinical Science*, **2016**, 130, 1535-44	6.5	10
91	Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. *Journal of Hepatology*, **2021**, 75, 935-959	13.4	10
90	Glycaemic, gastrointestinal, hormonal and appetitive responses to pearl millet or oats porridge breakfasts: a randomised, crossover trial in healthy humans. *British Journal of Nutrition*, **2019**, 122, 1142-1154	3.6	9
89	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury.. *Hepatology*, **2022**,	11.2	9
88	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. *Pharmacological Research*, **2021**, 164, 105404	10.2	9
87	HLA associations with infliximab-induced liver injury. *Pharmacogenomics Journal*, **2020**, 20, 681-686	3.5	8
86	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. *Alcohol*, **2018**, 66, 1-7	2.7	8
85	The detection of oesophageal varices using a novel, disposable, probe-based transnasal endoscope: a prospective diagnostic pilot study. *Liver International*, **2016**, 36, 1639-1648	7.9	8
84	Hepatotoxicity Related to Methotrexate **2013**, 593-604		8
83	Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk. *EClinicalMedicine*, **2021**, 34, 100835	11.3	8
82	Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine. *Digestive Diseases*, **2017**, 35, 314-322	3.2	7
81	Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort. *BMJ Open*, **2019**, 9, e027244	3	7

80	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. *Toxicology*, **2008**, 253, 10	4.4	7
79	Using MRI to study the alterations in liver blood flow, perfusion, and oxygenation in response to physiological stress challenges: Meal, hyperoxia, and hypercapnia. *Journal of Magnetic Resonance Imaging*, **2019**, 49, 1577-1586	5.6	7
78	The role of hepatic lipid composition in obesity-related metabolic disease. *Liver International*, **2021**,	7.9	7
77	Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac. *Pancreas*, **2015**, 44, 260-5	2.6	6
76	Zanubrutinib-induced liver injury: a case report and literature review. *BMC Gastroenterology*, **2021**, 21, 244	3	6
75	Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans. *Toxicological Sciences*, **2021**, 181, 23-34	4.4	6
74	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. *Journal of Hepatology*, **2021**, 75, 333-341	13.4	6
73	Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. *Journal of Hepatocellular Carcinoma*, **2017**, 4, 123-130	5.3	5
72	The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?. *Liver International*, **2013**, 33, 172-9	7.9	5
71	Defining @cute on chronic liver failure©an identity crisis!. *Indian Journal of Gastroenterology*, **2010**, 29, 177-80	1.9	5
70	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. *DNA and Cell Biology*, **2020**, 39, 349-354	3.6	5
69	Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. *JHEP Reports*, **2021**, 3, 100232	10.3	5
68	Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 1188-1197	6.1	5
67	Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis. *JHEP Reports*, **2021**, 3, 100317	10.3	5
66	Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	5
65	Jaundice: applying lessons from physiology. *Surgery*, **2009**, 27, 11-18	0.3	4
64	Diffuse nesidioblastosis causing hyperinsulinemic hypoglycemia: the importance of pancreatic sampling on EUS. *Gastrointestinal Endoscopy*, **2008**, 68, 571-2; discussion 572	5.2	4
63	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. *Journal of Hepatology*, **2021**,	13.4	4

62	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. *JHEP Reports*, **2022**, 4, 100409	10.3	4
61	Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms?. *Annals of Hepatology*, **2016**, 15, 277-82	3.1	4
60	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. *Journal of Hepatology*, **2021**,	13.4	4
59	Validation of the AASLD recommendations for classification of oesophageal varices in clinical practice. *Liver International*, **2020**, 40, 905-912	7.9	4
58	HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.. *Immunology*, **2022**,	7.8	4
57	Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.. *Biomedicines*, **2021**, 9,	4.8	4
56	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. *Annals of Internal Medicine*, **2017**, 166, 229-230	8	3
55	PS-112-Endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes. *Journal of Hepatology*, **2019**, 70, e70-e71	13.4	3
54	Immune-Mediated Drug-Induced Liver Injury **2014**, 401-412		3
53	Mind the gap. *ATLA Alternatives To Laboratory Animals*, **2010**, 38 Suppl 1, 1-4	2.1	3
52	Concurrent mucinous cystadenoma of the liver and bile duct: a rare cause of jaundice. *Gastrointestinal Endoscopy*, **2006**, 63, 870-2	5.2	3
51	Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. *Liver International*, **2021**, 41, 1565-1575	7.9	3
50	MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability. *Journal of Magnetic Resonance Imaging*, **2021**, 53, 1422-1431	5.6	3
49	Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
48	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. *United European Gastroenterology Journal*, **2018**, 6, 1372-1379	5.3	3
47	Drug-induced liver injury. *Medicine*, **2015**, 43, 590-593	0.6	2
46	The Evaluation and Use of a Food Frequency Questionnaire Among the Population in Trivandrum, South Kerala, India. *Nutrients*, **2020**, 12,	6.7	2
45	Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease. *Liver International*, **2018**, 38, 1832-1838	7.9	2

44	Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. *Gastroenterology*, **2018**, 154, 1848-1850	13.3	2
43	Drug-induced liver injury. *Medicine*, **2019**, 47, 734-739	0.6	2
42	Steering azathioprine safely: lessons from pharmacogenetics. *American Journal of Gastroenterology* , **2001**, 96, 3202-3	0.7	2
41	EUS-guided choledochoduodenostomy with electrocautery-enhanced lumen-apposing metal stents in patients with malignant distal biliary obstruction: multicenter collaboration from the United Kingdom and Ireland. *Gastrointestinal Endoscopy*, **2021**,	5.2	2
40	What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. *Rheumatology*, **2021**, 60, 5785-5794	3.9	2
39	Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan). *Gastrointestinal Nursing*, **2018**, 16, S15-S22	0.2	2
38	Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video). *Gastrointestinal Endoscopy*, **2021**, 94, 321-328	5.2	2
37	Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. *BMJ Open Gastroenterology*, **2021**, 8,	3.9	2
36	Drug Interactions in the Liver **2020**, 1050-1057		1
35	Jaundice: applying lessons from physiology. *Surgery*, **2011**, 29, 603-609	0.3	1
34	Portal hypertension and ascites. *Surgery*, **2007**, 25, 28-33	0.3	1
33	Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. *BMJ Open*, **2020**, 10, e041574	3	1
32	Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 1327-1343	5.5	1
31	Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study. *Liver International*, **2021**,	7.9	1
30	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
29	Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH).. *Frontline Gastroenterology*, **2022**, 13, 126-132	2.6	1
28	Reply to: "Hip fracture risk in patients with alcoholic cirrhosis: Do comorbidities and complications matter?". *Journal of Hepatology*, **2019**, 70, 213-214	13.4	1
27	The Effect of Covid-19 on Alcohol Use Disorder and the Role of Universal Alcohol Screening in an Inpatient Setting: A Retrospective Cohort Control Study. *Alcohol and Alcoholism*, **2021**,	3.5	1

26	Hepatic ADRs429-443		1
25	Epidemiology of Cirrhosis and Hepatocellular Carcinoma344-356		1
24	Pro-adrenomedullin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. *Scandinavian Journal of Gastroenterology*, **2020**, 55, 606-614	2.4	0
23	Jaundice: applying lessons from physiology. *Surgery*, **2014**, 32, 627-634	0.3	0
22	Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation. *BMJ Open*, **2021**, 11, e045802	3	0
21	Gut Microbial Profile Is Associated With Residential Settings and Not Nutritional Status in Adults in Karnataka, India. *Frontiers in Nutrition*, **2021**, 8, 595756	6.2	0
20	Large volume paracentesis: to do or where to do?. *Gut*, **2021**, 70, 2401-2402	19.2	0
19	Estimating the clinical prevalence of Wilson© disease in the UK. *JHEP Reports*, **2021**, 3, 100329	10.3	0
18	Long-term outcomes of liver transplant recipients followed up in non-transplant centres: Care closer to home. *Clinical Medicine*, **2021**, 21, e32-e38	1.9	0
17	The effect of exercise training on adipose tissue insulin sensitivity: A systematic review and meta-analysis.. *Obesity Reviews*, **2022**, e13445	10.6	0
16	Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *World Journal of Hepatology*, **2022**, 14, 1025-1037	3.4	0
15	Drug-Induced Cholestasis: Mechanisms and Importance **2017**, 117-128		
14	Commentary: non-alcoholic steatohepatitis-finding and minding the fire behind the smoke. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 209-211	6.1	
13	Portal hypertension and ascites. *Surgery*, **2014**, 32, 661-667	0.3	
12	Hepatic Adverse Drug Reactions **2014**, 539-555		
11	To feed or what to feed in cirrhosis?. *Hepatology*, **2012**, 56, 1590	11.2	
10	Portal hypertension and ascites. *Surgery*, **2011**, 29, 640-646	0.3	
9	Portal hypertension and ascites. *Surgery*, **2010**, 28, 234-240	0.3	

List of Publications

8	Comparison of the reverse bevel versus Franseen type endoscopic ultrasound needle. *World Journal of Gastrointestinal Endoscopy*, **2020**, 12, 266-275	2.2
7	Pharmacogenetics in Gastroenterology **2006**, 273-294	
6	Immune-Mediated Drug-Induced Liver Injury **2020**, 491-504	
5	Hepatic Adverse Drug Reactions459-474	
4	Magnetic Resonance Imaging Methods for Assessing Cirrhosis and Portal Hypertension **2018**, 211-223	
3	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. *Efficacy and Mechanism Evaluation*, **2022**, 9, 1-54	1.7
2	Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis.. *PLoS ONE* , **2022**, 17, e0268034	3.7
1	Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. *Thrombosis Research*, **2022**, 215, 19-29	8.2